At Charles River, we understand the challenges and complexities in the search of potential therapies for neurological disorders. Discovery from Charles River applies our multi-disciplinary skillset that spans biology, chemistry and pharmacology. Our portfolio of unique capabilities and state-of-the-art instrumentation can support and advance your central nervous system (CNS) research.
Our scientists have the depth and specialty expertise to deliver insight and data to progress your discovery program in all major neurodegenerative diseases and neurological indications, including depression, schizophrenia, Alzheimer’s disease, Parkinson’s disease, chronic pain, epilepsy, multiple sclerosis, stroke and ischemia. To improve the lives of patients impacted by deadly or debilitating rare or orphan diseases, such as ataxia, Rett syndrome and Batten disease, our scientists continuously develop innovative new models and assays to advance research in these neglected disease areas.
Our scientific team can guide you in selecting the appropriate disease model or assay, validating targets, identifying hits and optimizing leads. With our extensive portfolio, we can collaborate with you to develop novel study designs to meet your specific research needs. To further efficacy, metabolic, toxicokinetic and bioanalytical investigations, we offer fully validated in vitro services and capabilities. Our various new and cutting edge imaging modalities, comprehensive behavioral and biomarker endpoints, and translational tools enable more effective decision-making in development and help move your research forward.